ClinicalTrials.gg
RecruitingNCT07557498SPARC-HCMUpdated Apr 29, 2026

Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US

An observational study in Obstructive Hypertrophic Cardiomyopathy (oHCM), sponsored by Bristol-Myers Squibb. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Bristol-Myers Squibb · Observational

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
362
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb — 10 open to participants now, 15 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · Bristol-Myers Squibb.

Planned enrollment
6th of 15
362 · median 200
Started
2026
with 4 others
Observational
15 of 32
9 open now
Primary completion
2026-12
later than 5 of 14 live
Registered
30th of 32
by date

Among the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, this one is the 6th largest by planned enrollment of the 15 observational ones that give a count, is one of 5 that started in 2026, is one of 15 observational ones, reaches primary completion later than 5 of the 14 other live ones, and was the 30th registered.

Cardiomyopathy, Hypertrophic

364 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 117 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

10 of the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten, and to understand patient and physician experiences with mavacamten treatment, in the US community-based practice

03

Conditions studied

  • Obstructive Hypertrophic Cardiomyopathy (oHCM)

Keywords

  • Obstructive Hypertrophic cardiomyopathy (oHCM)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of adults that have been diagnosed with obstructive hypertrophic cardiomyopathy (HCM) and have received treatment with mavacamten and their treating clinicians from participating community-based sites in the US.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phase I: retrospective chart review

For inclusion in the study, participants must meet ALL of the following criteria:

  • Are an adult aged 18 or over at baseline
  • Have a confirmed diagnosis of obstructive hypertrophic cardiomyopathy (HCM)
  • Have been prescribed mavacamten for obstructive HCM at one of the study sites between 28th April 2022 and 31st December 2024
  • Have not ever been enrolled in any interventional clinical trial involving any cardiac myosin inhibitor (enrollment in observational studies is permitted)
  • Are not enrolled in any interventional clinical trial at study baseline

Phase II: patient survey • Participants must meet all inclusion criteria of Phase I: retrospective chart review and be able to read and understand English and have access to computer or smartphone to complete the survey

Exclusion criteria

Exclusion Criteria:

  • None with the proviso that all inclusion criteria are met.
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
362 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1

    Participants with obstructive hypertrophic cardiomyopathy (oHCM) receiving mavacamten

    Drug: Mavacamten

  • Group 2

    Physicians treating patients diagnosed with obstructive hypertrophic cardiomyopathy (oHCM)

    Drug: Mavacamten

Interventions

06

What researchers measure

Primary outcomes

  1. Participant blood pressure (both systolic and diastolic)

    Group 1 only

    Time frame: Baseline

  2. Date of diagnosis of hypertrophic cardiomyopathy

    Group 1 only

    Time frame: Baseline

  3. Hypertrophic cardiomyopathy genetic testing results

    Group 1 only

    Time frame: Baseline

  4. Family history of hypertrophic cardiomyopathy

    Group 1 only

    Time frame: Baseline

  5. Family history of Sudden Cardiac Death (SCD)

    Group 1 only

    Time frame: Baseline

  6. Participant comorbidities (cardiovascular and non-cardiovascular )

    Group 1 only

    Time frame: Baseline

  7. Type of prior surgeries and procedures

    Group 1 only. Prior surgeries and procedures include: Septal Reduction Therapy (SRT), surgeries (valve repair/placement, left atrial appendage ligation), placement of devices (Implantable Cardioverter Defibrillator (ICD), pacemaker and cardiac resynchronization therapy) or atrial fibrillation/flutter ablation

    Time frame: Baseline and up to week 24

  8. Participant New York Heart Association (NYHA) class category

    Group 1 only

    Time frame: Baseline, and at weeks 4, 8, 12, 24

  9. Change in participant New York Heart Association (NYHA) class from baseline

    Group 1 only

    Time frame: Baseline, and at weeks 4, 8, 12, 24

  10. Duration of mavacamten treatment

    Group 1 only

    Time frame: Baseline, and at weeks 4, 8, 12, 24

  11. Number of mavacamten dose titrations

    Group 1 only

    Time frame: Baseline, and at weeks 4, 8, 12, 24

  12. Type of mavacamten dose tritration

    Group 1 only

    Time frame: Baseline, and at weeks 4, 8, 12, 24

  13. Clinical reason for mavacamten dose titration

    Group 1 only

    Time frame: Baseline, and at weeks 4, 8, 12, 24

  14. Clinical reason for mavacamten treatment discontinuation

    Group 1 only

    Time frame: Baseline, and at weeks 4, 8, 12, 24

  15. Left Ventricular Ejection Fraction (LVEF) recovery after mavacamten discontinuation if discontinued due to LVEF<50%,

    Group 1 only

    Time frame: Baseline, and at weeks 4, 8, 12, 24

  16. Time from mavacamten discontinuation to Left Ventricular Ejection Fraction (LVEF) recovery

    Group 1 only

    Time frame: Baseline, and at weeks 4, 8, 12, 24

  17. Clinical reason for temporary mavacamten treatment interuption

    Group 1 only

    Time frame: Baseline, and at weeks 4, 8, 12, 24

  18. Time to temporary mavacamten treatment interruption

    Group 1 only

    Time frame: Baseline, and at weeks 4, 8, 12, 24

  19. Left Ventricular Ejection Fraction (LVEF) recovery after mavacamten interruption if the interruption was due to LVEF<50%

    Group 1 only

    Time frame: Baseline, and at weeks 4, 8, 12, 24

  20. Time from mavacamten treatment interruption to Left Ventricular Ejection Fraction (LVEF) recovery

    Group 1 only

    Time frame: Baseline, and at weeks 4, 8, 12, 24

  21. Time to mavacamten treatment resumption

    Group 1 only

    Time frame: Baseline, and at weeks 4, 8, 12, 24

  22. Type of hypertrophic cardiomyopathy (HCM) background therapy prescribed

    Group 1 only

    Time frame: Baseline, and at weeks 4, 8, 12, 24

  23. Type of changes to hypertrophic cardiomyopathy (HCM) background therapy

    Group 1 only. Type of changes include initiation, switching, discontinuation, augmentation, dose titration

    Time frame: At baseline, weeks 4, 8, 12, 24

Secondary outcomes

  1. Perspectives on treatment preference, and the eligibility, onboarding and implementation of mavacamten as assessed by feedback collated through structured physician interviews

    Group 2 only

    Time frame: Up to week 24

07

Study locations

1 of 1 sites recruiting
  • Adelphi Real World
    Bollington, Macclesfield SK10 5JB, United Kingdom
    Recruiting
    • USA Generic Country, Site 0001 · Contact0000000000
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.

Of 82 observational studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 43. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2026
First posted
Apr 29, 2026
StartActual
Jan 15, 2026
Primary completionEst.
Dec 14, 2026
CompletionEst.
Jun 17, 2027
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07557498
Responsible party
Sponsor
First posted
Apr 29, 2026
Start date
Jan 15, 2026
Primary completion
Dec 14, 2026 (estimated)
Completion
Jun 17, 2027 (estimated)
Last update
Apr 29, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion